Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results, Beats Expectations By $0.09 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) issued its earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09, Zacks reports. The company had revenue of $26.90 million during the quarter.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock traded up $0.03 during trading on Thursday, reaching $1.79. The company had a trading volume of 1,010,820 shares, compared to its average volume of 1,806,906. The company has a market cap of $127.56 million, a price-to-earnings ratio of -0.72 and a beta of 1.75. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $16.27. The firm has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $2.87.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of several research reports. Wells Fargo & Company cut their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group lowered their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.24.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns purchased 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.